Physician profile
Irl Lawrence Extein
NPI 1801962675
$3,216.13
in general payments reported to CMS, 2019-2025
17 companies · $801 in 2025
The $801 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $979 · 2020: $244 · 2023: $477 · 2024: $715 · 2025: $801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,993.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $501.11 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $473.76 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $442.60 | 2020-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $332.80 | 2019-2025 | Rexulti |
| Abbvie INC. | $298.39 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $249.23 | 2023-2025 | Caplyta |
| Avanir Pharmaceuticals, INC. | $203.47 | 2019-2020 | |
| Allergan, INC. | $160.57 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $153.85 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $124.12 | 2023-2025 | Lybalvi |
| Janssen Pharmaceuticals, INC | $116.52 | 2019 | |
| Almatica Pharma LLC | $38.32 | 2025 | Loreev Xr |
| Shire North American Group INC | $31.52 | 2019 | |
| Tempus Ai, INC | $26.75 | 2024 | |
| Vanda Pharmaceuticals INC. | $24.24 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $22.00 | 2023 | Vns Therapy Symmetry Model 8103 Generator |
| Alfasigma USA, INC. | $16.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irl Extein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.